Tag: Amyotrophic Lateral Sclerosis
Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical...
Usnoflast is a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)
Zydus Lifesciences completes Phase II(a) clinical trial of Usnoflast in ALS...
Usnoflast, a novel oral NLRP3 inflammasome inhibitor, shows promising results in reducing neurodegeneration and improving key health markers
Scientists gain new insight into neurodegenerative diseases using fruit flies
Taking cues from earlier research studies which had demonstrated that reduced Ataxin-2 levels in mice pre-disposed to ALS-like illness slowed down their onset and progression of neurodegeneration, the scientists focused on a particular protein............